Further details of Flurizan's failure in Alzheimer's revealed
This article was originally published in Scrip
Executive Summary
Further details of Myriad Genetics' failed Phase III trial of Flurizan (tarenflurbil), its investigational treatment for Alzheimer's disease, have been revealed in a presentation at the International Conference on Alzheimer's Disease (ICAD) in Chicago.